| Autor: |
Pichon, Maxime, Cremniter, Julie, Burucoa, Christophe, Abdallah, Sahar, Alauzet, Corentine, Alix, Tom, Allouche, Kahina, Amara, Marlène, Anglade, Florence, Anguel, Nadia, Armand-Lefevre, Laurence, Barbier, Francois, Beauruelle, Clémence, Bemer, Pascale, Benmansour, Hanaa, Bercot, Béatrice, Bergon, Ludovic, Bertei, Dominique, Berthon, Marc, Beuret, Pascal |
| Předmět: |
|
| Zdroj: |
Annals of Clinical Microbiology & Antimicrobials; 6/28/2023, Vol. 22 Issue 1, p1-11, 11p |
| Abstrakt: |
Background: Description and comparison of bacterial characteristics of ventilator-associated pneumonia (VAP) between critically ill intensive care unit (ICU) patients with COVID-19-positive, COVID + ; and non-COVID-19, COVID-. Methods: Retrospective, observational, multicenter study that focused on French patients during the first wave of the pandemic (March–April 2020). Results: 935 patients with identification of at least one bacteriologically proven VAP were included (including 802 COVID +). Among Gram-positive bacteria, S. aureus accounted for more than two-thirds of the bacteria involved, followed by Streptococcaceae and enterococci without difference between clinical groups regarding antibiotic resistance. Among Gram-negative bacteria, Klebsiella spp. was the most frequently observed bacterial genus in both groups, with K. oxytoca overrepresented in the COVID- group (14.3% vs. 5.3%; p < 0.05). Cotrimoxazole-resistant bacteria were over-observed in the COVID + group (18.5% vs. 6.1%; p <0.05), and after stratification for K. pneumoniae (39.6% vs. 0%; p <0.05). In contrast, overrepresentation of aminoglycoside-resistant strains was observed in the COVID- group (20% vs. 13.9%; p < 0.01). Pseudomonas sp. was more frequently isolated from COVID + VAPs (23.9% vs. 16.7%; p <0.01) but in COVID- showed more carbapenem resistance (11.1% vs. 0.8%; p <0.05) and greater resistance to at least two aminoglycosides (11.8% vs. 1.4%; p < 0.05) and to quinolones (53.6% vs. 7.0%; p <0.05). These patients were more frequently infected with multidrug-resistant bacteria than COVID + (40.1% vs. 13.8%; p < 0.01). Conclusions: The present study demonstrated that the bacterial epidemiology and antibiotic resistance of VAP in COVID + is different from that of COVID- patients. These features call for further study to tailor antibiotic therapies in VAP patients. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink